Biosimilars Market: Interchangeability, Patent Expiry and the Checkpoint Inhibitor Pipeline
The Biosimilars Market comprises biological medicines shown to be highly similar to an already approved reference biologic, with no clinically meaningful differences in safety, purity or potency. In the US, they are approved through the abbreviated 351(k) pathway established under the Biologics Price...
